

Morgan, Lewis & Bockius LLP
1111 Pennsylvania Avenue, NW
Washington, DC 20004
Tel. 202.739.3000
Fax: 202.739.3001
www.morganlewis.com

Morgan Lewis

COUNSELORS AT LAW

FEDERAL FAX CENTER

JUL 16 2004

OFFICIAL

FAX MESSAGE**Send To:**

Name: **Examiner J. Parkin, Ph.D.
Group 1648**
Firm: **U.S. Patent and Trademark Office**

FAX Number: **571-273-0908**

Telephone Number: **571-272-0908**

From:

Name **Sally P. Teng**

Floor:

Operator Sending:

Telephone Number: **202-739-5734**

Time Sent:

Date Sent: **July 16, 2004**

Number of Pages (INCLUDING COVER PAGE): **7**

Note:

THE INFORMATION CONTAINED IN THIS FAX MESSAGE IS INTENDED ONLY FOR THE PERSONAL AND CONFIDENTIAL USE OF THE RECIPIENT(S) NAMED ABOVE. THIS MESSAGE MAY BE AN ATTORNEY-CLIENT COMMUNICATION AND AS SUCH IS PRIVILEGED AND CONFIDENTIAL. IF THE READER OF THIS MESSAGE IS NOT THE INTENDED RECIPIENT OR AN AGENT RESPONSIBLE FOR DELIVERING IT TO THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT YOU HAVE RECEIVED THIS DOCUMENT IN ERROR AND THAT ANY REVIEW, DISSEMINATION, DISTRIBUTION, OR COPYING OF THIS MESSAGE IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR, PLEASE NOTIFY US IMMEDIATELY BY TELEPHONE, AND RETURN THE ORIGINAL MESSAGE TO US BY MAIL. THANK YOU.

Re:

**U.S. Patent Application of Lise THIBODEAU et al.
U.S. Serial No. 09/832,806
Filed: August 4, 2000
For: USE OF HIV-1 gp120 AND gp160
PROTEINS MODIFIED IN THE V3 LOOP
FOR THE PREPARATION OF VACCINE
COMPOSITIONS AND FORMULATIONS
CONTAINING THE SAME**

Group 1648

Examiner: J. Parkin, Ph.D.

Comments

PATENT
ATTORNEY DOCKET NO.: 045636-5039

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION of:

Lise THIBODEAU *et al.*

Application No.: 09/632,806

Filed: August 4, 2000

FOR: USE OF HIV-1 gp120 AND gp160 PROTEINS
MODIFIED IN THE V3 LOOP FOR THE
PREPARATION OF VACCINE
COMPOSITIONS AND FORMULATIONS
CONTAINING THE SAME

)
)
)
)
) Group Art Unit: 1648

)
) Examiner: J. Parkin, Ph.D.
)
)
)

AMENDMENT (FEE) TRANSMITTAL FORM

1. Transmitted herewith is a Supplemental Amendment Under 37 C.F.R. § 1.111.

2. Additional papers enclosed:

- ☐ Information Disclosure Statement
- ☐ Form PTO-1449, copies of ___ references
- ☐ Citations
- ☐ Declaration of Biological Deposit
- ☐ Submission of "Sequence Listing", computer readable copy and/or amendment pertaining thereto for biotechnology invention containing nucleotide and/or amino acid sequence.
- ☐ Drawings: ☐ Formal ☐ Informal (Correction)

ATTORNEY DOCKET NO.: 045636-5039
 Application No.: 09/632,806
 Page 2

3. Extension of Time

The proceedings herein are for a patent application and the provisions of 37 C.F.R. § 1.136(a) apply.

- ☒ Applicant believes that no extension of time is required. However, this conditional petition is being made to provide for the possibility that applicant has inadvertently overlooked the need for a petition and fee for extension of time.
- ☐ Applicant petitions for an extension of time, the fees for which are set out in 37 C.F.R. § 1.17(a), for the total number of months checked below:

<u>Total Months Requested</u>	<u>Fee for Extension</u>	<u>Fee for Small Entity</u>
<input type="checkbox"/> one month	\$ 110.00	\$ 55.00
<input type="checkbox"/> two months	\$ 420.00	\$210.00
<input type="checkbox"/> three months	\$ 950.00	\$475.00
<input type="checkbox"/> four months	\$1,480.00	\$740.00
<input type="checkbox"/> five months	\$2,010.00	\$1,005.00

If an additional extension of time is required, please consider this a Petition therefor.

- ☐ An extension for _____ months has already been secured and the fee paid therefor of \$_____ is deducted from the total fee due for the total months of extension now requested.

Extension of time fee due with this request: \$0.00

4. Constructive Petition

- ☒ EXCEPT for issue fees payable under 37 C.F.R. § 1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§ 1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account 50-0310. This paragraph is intended to be a CONSTRUCTIVE PETITION FOR EXTENSION OF TIME in accordance with 37 C.F.R. § 1.136(a)(3).

ATTORNEY DOCKET NO.: 045636-5039
 Application No.: 09/632,806
 Page 3

5. Fee Calculation (37 C.F.R. §1.16) (SMALL ENTITY)

CLAIMS AS AMENDED						
	Claims Remaining After Amendment		Highest No. Previously Paid	Present Extra	at Rate of	Total Fees
Total Claims (37 C.F.R. §1.16(c))	9	minus	20	0	x \$18/\$9 each=	\$ 0.00
Independent Claims (37 C.F.R. §1.16(b))	1	minus	3	0	x \$86/\$43 each=	\$ 0.00
<input type="checkbox"/> First presentation of Multiple dependent claim(s)					\$290/\$145	\$ 0.00
SUB-TOTAL =						\$ 0.00
Fee for <u>0</u> Month Extension of Time						\$ 0.00
Reduction by 1/2 for filing by a small entity						\$ 0.00
TOTAL FEE =						\$ 0.00


6. Fee Payment

- ☒ No fee is to be paid at this time.
- ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, including fees due under 37 C.F.R. §§ 1.16 and 1.17, or credit any overpayment to Deposit Account 50-0310.

Respectfully Submitted,
Morgan Lewis & Bockius LLP

Date: July 16, 2004
 Morgan Lewis & Bockius LLP
 Customer No. 09629
 1111 Pennsylvania Avenue, N.W.
 Washington, D.C. 20004
 Tel. No.: 202-739-3000
 SPT:mk

By:


 Sally P. Teng, Ph.D.
 Registration No. 45,397
 Tel. No.: (202) 739-5734
 Fax No.: (202) 739-3001

PATENT
Attorney Docket No. 045636-5039

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Lise THIBODEAU *et al.*

Application No.: 09/632,806

Filed: August 4, 2000

For: USE OF HIV-1 gp120 AND gp160 PROTEINS
MODIFIED IN THE V3 LOOP FOR THE
PREPARATION OF VACCINE COMPOSITIONS
AND FORMULATIONS CONTAINING THE SAME

)
)
)
)
) Group Art Unit: 1648

) Examiner: J. Parkin, Ph.D.
)
)
)
)

Commissioner for Patents
U.S. Patent and Trademark office
2011 South Clark Place
Customer Window
Crystal Plaza Two, Lobby, Room 1B03
Arlington, VA 22202

RECEIVED
CENTRAL FAX CENTER
JUL 16 2004

OFFICIAL

Sir:

SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.111

This amendment supplements the amendment filed on April 26, 2004, in response to the Office Action, dated February 26, 2004.

Upon further review of the specification, Applicants noticed that the response did not include all the missing sequence identifiers. This Supplemental Amendment provides all the required sequence identifiers and places the application in condition for allowance.

Applicants respectfully request reconsideration of this application in view of the following amendment and remarks.

Please amend the above-identified application as follows:

Amendments to the Specification begin on page 2 of this paper.

Remarks/Arguments begin on page 3 of this paper.